| Literature DB >> 33312421 |
Ashutosh Gupta1, Abhay K Pandey2.
Abstract
BACKGROUND: Aceclofenac (ACF), a widely used nonsteroidal anti-inflammatory drug, has been associated with a number of severe cases of clinical hepatotoxicity. Terminalia bellirica, an evergreen tree, is known to have several ethnomedicinal uses including antioxidant and hepatoprotective effects. Hence T. bellirica fruit extracts and its phytoconstituent ellagic acid (EA) are expected to provide protection against oxidative stress and liver damage produced by long-term use of ACF. AIM: To evaluate the antioxidant and hepatoprotective activities of T. bellirica fruit extracts and EA against ACF-induced toxicity in albino Wistar rats.Entities:
Keywords: Aceclofenac; Antioxidant; Ellagic acid; Hepatotoxicity; Histopathology; Terminalia bellirica
Year: 2020 PMID: 33312421 PMCID: PMC7701975 DOI: 10.4254/wjh.v12.i11.949
Source DB: PubMed Journal: World J Hepatol
Figure 1The chelating activity was measured at different concentrations (50-250 μg/ml). Butylated hydroxytoluene was included for comparison and absorbance was measured at 562 nm. Results are presented as mean ± SD of triplicates. aP < 0.05 as compared to butylated hydroxytoluene.
Figure 2Butylated hydroxytoluene was included as a standard and absorbance was measured at 546 nm. Results are presented as mean ± SD of triplicates. aP < 0.05 as compared to butylated hydroxytoluene.
Figure 3Percentage inhibition of lipid peroxidation in rat liver homogenate by Butylated hydroxytoluene (2 mg/mL) was included for comparison and accounted for approximately 85% lipid peroxidation inhibition. The results are shown as mean ± SD of triplicates (aP < 0.05).
Effect of Terminalia bellirica fruit extracts and ellagic acid on body weight and liver weight of aceclofenac treated rats
|
|
|
|
|
| Group I | 18.83 ± 1.15 | 4.62 ± 0.16 | 2.85 ± 0.29 |
| Group II | -20.50 ± 6.87 | 6.56 ± 0.41 | 3.95 ± 1.29 |
| Group III | -09.17 ± 3.78 | 4.82 ± 0.19 | 3.05 ± 0.35 |
| Group IV | -11.06 ± 3.77 | 5.17 ± 0.87 | 3.13 ± 0.46 |
| Group V | -18.50 ± 6.26 | 5.70 ± 1.09 | 3.44 ± 0.58 |
| Group VI | -14.83 ± 3.21 | 5.03 ± 0.95 | 3.21 ± 0.64 |
Group I: Control rats; Group II: Aceclofenac (ACF) treated rats; Group III: ACF + Silymarin treated rats; Group IV: ACF + Ellagic acid treated rats; Group V: ACF + Aqueous extract treated rats; Group VI: ACF + Ethyl acetate extract treated rats. Each value is expressed as mean ± SD (n = 5). Silymarin was used as a positive control.
Represents a significant difference compared with the control (aP < 0.0001).
Represents a significant difference compared with group II (bP < 0.005).
Figure 4Effect of Group I-normal control; Group II-Aceclofenac (ACF) treated rats; Group III-ACF + Silymarin treated rats; Group IV-ACF + Ellagic acid treated rats; Group V- ACF + Aqueous extract treated rats; Group VI: ACF + Ethyl acetate extract treated rats. Silymarin was used as a positive control. The data are represented as mean ± SD (n = 5, aP < 0.01; bP < 0.05 as compared to group II).
Effect of Terminalia bellirica fruit extracts and ellagic acid on serum hepatic function markers in aceclofenac treated rats
|
|
|
|
|
|
|
|
|
|
| Group I | 6.05 ± 0.45 | 87.16 ± 14.19 | 69.37 ± 10.24 | 58.19 ± 09.13 | 1.71 ± 0.37 | 0.80 ± 0.33 | 304.76 ± 10.23 | 4.27 ±1.08 |
| Group II | 3.64 ± 0.14 | 157.32 ± 26.16 | 165.40 ± 12.51 | 158.43 ± 8.24 | 6.87 ± 0.22 | 3.12 ± 1.31 | 689.34 ± 11.21 | 9.29 ± 2.15 |
| Group III | 5.72 ± 0.17 | 93.49 ± 9.08 | 85.21 ± 16.34 | 69.09 ± 4.71 | 2.32 ± 0.13 | 1.37 ± 0.18 | 401.19 ± 3.89 | 5.87 ± 0.24 |
| Group IV | 5.52 ± 0.31 | 96.65 ± 11.25 | 89.56 ± 9.13 | 74.98 ± 11.38 | 2.34 ± 0.24 | 1.49 ± 0.17 | 449.54 ± 15.09 | 6.18 ± 0.51 |
| Group V | 4.75 ± 0.38 | 121.49 ± 16.13 | 140.17 ± 4.75 | 132.11 ± 14.17 | 3.38 ± 0.52 | 2.72 ± 0.18 | 587.37 ± 7.94 | 7.69 ± 0.27 |
| Group VI | 5.60 ± 0.11 | 107.17 ± 12.37 | 113.6 ± 4.89 | 109.25 ± 04.85 | 2.53 ± 0.19 | 2.16 ± 0.06 | 505.18 ± 11.45 | 6.68 ± 0.39 |
Group-I: Control rats; Group-II: Aceclofenac (ACF) treated rats; Group-III: ACF + Silymarin treated rats; Group-IV: ACF + Ellagic acid treated rats; Group-V: ACF + Aqueous extract treated rats; Group-VI: ACF + Ethyl acetate extract treated rats. Each value is expressed as mean ± SD (n = 5). Silymarin was used as a positive control. ALP: Alkaline phosphatase; LDH: Lactate dehydrogenase; GGT: Glutamyl transferase.
Represents a significant difference compared with the control.
P < 0.0001.
Represents a significant difference compared with group II.
P < 0.0005.
P < 0.005.
Figure 5Histopathological changes in liver slices after oral administration of A: Control; B: Aceclofenac (ACF) treated rats; C: ACF + Silymarin treated rats; D: ACF + Ellagic acid treated rats; E: ACF + Aqueous extract treated rats; and F: ACF + Ethyl acetate extract treated rats. The blue color arrow represents central vain, black arrow represents a nucleus and the yellow arrow represents inflammatory cells.
Effect of Terminalia bellirica fruit extracts and ellagic acid on antioxidant markers in liver tissue homogenate of aceclofenac treated rats
|
|
|
|
|
| Group I | 2.68 ± 0.08 | 31.09 ± 0.71 | 8.45 ± 0.17 |
| Group II | 18.63 ± 1.43 | 12.04 ± 1.49 | 3.21 ± 0.84 |
| Group III | 4.50 ± 0.18 | 29.11 ± 0.35 | 7.59 ± 0.41 |
| Group IV | 6.74 ± 0.14 | 27.24 ± 0.57 | 7.19 ± 0.37 |
| Group V | 12.28 ± 0.12 | 19.80 ± 0.62 | 5.77 ± 1.19 |
| Group VI | 9.46 ± 0.19 | 21.15 ± 0.49 | 6.23 ± 0.92 |
Group-I: Control rats; Group-II: Aceclofenac (ACF) treated rats; Group-III: ACF + Silymarin treated rats; Group-IV: ACF + Ellagic acid treated rats; Group-V: ACF + Aqueous extract treated rats; Group-VI: ACF + Ethyl acetate extract treated rats. Each value is expressed as mean ± SD (n = 5). Silymarin was used as a positive control. SOD: Superoxide dismutase; MDA: Malondialdehyde.
Represents a significant difference compared with the control (1P < 0.0001).
Represents a significant difference compared with group II.
P < 0.0001.
P < 0.005.